vs

Side-by-side financial comparison of DSS, INC. (DSS) and IMMUCELL CORP (ICCC). Click either name above to swap in a different company.

IMMUCELL CORP is the larger business by last-quarter revenue ($5.5M vs $4.1M, roughly 1.3× DSS, INC.). IMMUCELL CORP runs the higher net margin — -2.5% vs -420.6%, a 418.1% gap on every dollar of revenue. On growth, IMMUCELL CORP posted the faster year-over-year revenue change (-8.4% vs -23.8%). Over the past eight quarters, IMMUCELL CORP's revenue compounded faster (3.9% CAGR vs 3.2%).

DSS, Inc. is a diversified technology company offering product authentication solutions, secure identification services, blockchain-based innovation, digital asset management tools, and healthcare technology products. It primarily serves North American, Asian, and European markets across consumer goods, financial services, and healthcare core segments.

ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.

DSS vs ICCC — Head-to-Head

Bigger by revenue
ICCC
ICCC
1.3× larger
ICCC
$5.5M
$4.1M
DSS
Growing faster (revenue YoY)
ICCC
ICCC
+15.4% gap
ICCC
-8.4%
-23.8%
DSS
Higher net margin
ICCC
ICCC
418.1% more per $
ICCC
-2.5%
-420.6%
DSS
Faster 2-yr revenue CAGR
ICCC
ICCC
Annualised
ICCC
3.9%
3.2%
DSS

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
DSS
DSS
ICCC
ICCC
Revenue
$4.1M
$5.5M
Net Profit
$-17.4M
$-139.7K
Gross Margin
42.9%
Operating Margin
-98.1%
0.4%
Net Margin
-420.6%
-2.5%
Revenue YoY
-23.8%
-8.4%
Net Profit YoY
47.2%
80.1%
EPS (diluted)
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DSS
DSS
ICCC
ICCC
Q4 25
$4.1M
Q3 25
$6.4M
$5.5M
Q2 25
$5.3M
$6.4M
Q1 25
$5.0M
$8.1M
Q4 24
$5.4M
$7.8M
Q3 24
$5.6M
$6.0M
Q2 24
$4.2M
$5.5M
Q1 24
$3.9M
$7.3M
Net Profit
DSS
DSS
ICCC
ICCC
Q4 25
$-17.4M
Q3 25
$-2.2M
$-139.7K
Q2 25
$-2.6M
$501.9K
Q1 25
$-5.3M
$1.4M
Q4 24
$-32.9M
Q3 24
$-5.3M
$-701.7K
Q2 24
$-4.7M
$-1.5M
Q1 24
$-4.1M
$-437.9K
Gross Margin
DSS
DSS
ICCC
ICCC
Q4 25
Q3 25
42.9%
Q2 25
43.7%
Q1 25
41.6%
Q4 24
36.5%
Q3 24
26.3%
Q2 24
22.5%
Q1 24
31.6%
Operating Margin
DSS
DSS
ICCC
ICCC
Q4 25
-98.1%
Q3 25
-50.6%
0.4%
Q2 25
-64.8%
8.8%
Q1 25
-75.2%
13.9%
Q4 24
-522.7%
8.0%
Q3 24
-83.4%
-9.6%
Q2 24
-117.2%
-25.3%
Q1 24
-120.9%
-4.1%
Net Margin
DSS
DSS
ICCC
ICCC
Q4 25
-420.6%
Q3 25
-34.9%
-2.5%
Q2 25
-49.3%
7.8%
Q1 25
-106.9%
17.9%
Q4 24
-606.7%
Q3 24
-94.4%
-11.7%
Q2 24
-111.2%
-28.0%
Q1 24
-105.2%
-6.0%
EPS (diluted)
DSS
DSS
ICCC
ICCC
Q4 25
Q3 25
$-0.02
Q2 25
$0.06
Q1 25
$0.16
Q4 24
$-4.64
$0.09
Q3 24
$-0.75
$-0.09
Q2 24
$-0.66
$-0.20
Q1 24
$-0.58
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DSS
DSS
ICCC
ICCC
Cash + ST InvestmentsLiquidity on hand
$8.9M
$3.9M
Total DebtLower is stronger
$44.7M
$9.5M
Stockholders' EquityBook value
$-832.0K
$29.8M
Total Assets
$67.6M
$45.7M
Debt / EquityLower = less leverage
0.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DSS
DSS
ICCC
ICCC
Q4 25
$8.9M
Q3 25
$8.7M
$3.9M
Q2 25
$12.4M
Q1 25
$17.3M
Q4 24
$14.3M
$3.8M
Q3 24
$18.9M
Q2 24
$20.3M
$1.3M
Q1 24
$17.7M
$960.3K
Total Debt
DSS
DSS
ICCC
ICCC
Q4 25
$44.7M
Q3 25
$50.2M
$9.5M
Q2 25
$43.9M
Q1 25
$49.3M
$8.7M
Q4 24
$57.2M
$9.0M
Q3 24
$9.4M
Q2 24
$9.8M
Q1 24
$10.2M
Stockholders' Equity
DSS
DSS
ICCC
ICCC
Q4 25
$-832.0K
Q3 25
$14.2M
$29.8M
Q2 25
$15.7M
$29.9M
Q1 25
$17.9M
$29.0M
Q4 24
$19.9M
$27.5M
Q3 24
$52.1M
$26.4M
Q2 24
$55.2M
$23.5M
Q1 24
$59.9M
$24.6M
Total Assets
DSS
DSS
ICCC
ICCC
Q4 25
$67.6M
Q3 25
$92.1M
$45.7M
Q2 25
$93.4M
$46.7M
Q1 25
$92.4M
$45.6M
Q4 24
$106.5M
$45.1M
Q3 24
$142.7M
$44.4M
Q2 24
$144.4M
$41.9M
Q1 24
$148.5M
$43.1M
Debt / Equity
DSS
DSS
ICCC
ICCC
Q4 25
Q3 25
3.54×
0.32×
Q2 25
2.80×
Q1 25
2.76×
0.30×
Q4 24
2.87×
0.33×
Q3 24
0.36×
Q2 24
0.42×
Q1 24
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DSS
DSS
ICCC
ICCC
Operating Cash FlowLast quarter
$-1.6M
$-1.2M
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-32.3%
Capex IntensityCapex / Revenue
10.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$715.4K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DSS
DSS
ICCC
ICCC
Q4 25
$-1.6M
Q3 25
$-8.0M
$-1.2M
Q2 25
$2.1M
$1.6M
Q1 25
$-1.6M
$1.6M
Q4 24
$-2.9M
$-3.1K
Q3 24
$-315.0K
$-639.3K
Q2 24
$-3.4M
$581.8K
Q1 24
$-2.1M
$418.5K
Free Cash Flow
DSS
DSS
ICCC
ICCC
Q4 25
Q3 25
$-8.1M
$-1.8M
Q2 25
$2.0M
$1.4M
Q1 25
$-1.7M
$1.2M
Q4 24
$-3.0M
$-199.3K
Q3 24
$-727.7K
Q2 24
$-3.5M
$471.0K
Q1 24
$-2.2M
$348.1K
FCF Margin
DSS
DSS
ICCC
ICCC
Q4 25
Q3 25
-126.5%
-32.3%
Q2 25
37.4%
22.4%
Q1 25
-34.1%
15.4%
Q4 24
-54.9%
-2.6%
Q3 24
-12.1%
Q2 24
-81.9%
8.6%
Q1 24
-55.6%
4.8%
Capex Intensity
DSS
DSS
ICCC
ICCC
Q4 25
Q3 25
1.3%
10.8%
Q2 25
1.7%
2.4%
Q1 25
1.0%
4.1%
Q4 24
1.9%
2.5%
Q3 24
0.0%
1.5%
Q2 24
0.6%
2.0%
Q1 24
0.1%
1.0%
Cash Conversion
DSS
DSS
ICCC
ICCC
Q4 25
Q3 25
Q2 25
3.19×
Q1 25
1.09×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons